• 简

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    The Bull Case For DexCom (DXCM) Could Change Following Expanded Type 2 CGM Reimbursement Access - Learn Why

    Simply Wall St·08/18/2026 17:24:29
    语音播报
    • Earlier this year, DexCom highlighted that expanded insurance reimbursement now gives its continuous glucose monitoring systems access to a large group of type 2 non-insulin diabetes patients, while recent Q2 clinical data and product updates underscored the medical benefits of broader CGM use.
    • This combination of wider coverage and strong evidence base is reshaping expectations for DexCom’s long-term demand profile and business mix, even as competition and pricing uncertainties remain important constraints.
    • Against this backdrop, we’ll explore how expanded reimbursement for type 2 non-insulin patients could influence DexCom’s investment narrative and future assumptions.

    AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

    DexCom Investment Narrative Recap

    To own DexCom, you have to believe continuous glucose monitoring can keep gaining traction across both type 1 and type 2 non insulin diabetes, and that DexCom can defend its premium against rising competition and potential Medicare pricing pressure. The latest news around expanded reimbursement and strong Q2 data supports the long term demand story, but it does not remove near term uncertainty around how CMS competitive bidding and rival CGM offerings could influence the most important catalyst and risk.

    Among recent announcements, the CONNECT trial stands out here. The trial showed DexCom G7 meaningfully improved A1C outcomes in type 2 patients not using insulin, which directly reinforces the case for broader reimbursement and use in that growing population. For investors watching whether expanded coverage will translate into real world adoption and sustained revenue growth, this clinical evidence is a key piece of the puzzle that interacts closely with both the upside potential and the valuation debate now unfolding.

    Yet even with these positives, investors should be aware of how potential CMS competitive bidding could reshape DexCom’s Medicare economics and...

    Read the full narrative on DexCom (it's free!)

    DexCom's narrative projects $6.8 billion revenue and $1.5 billion earnings by 2029. This requires 11.2% yearly revenue growth and an earnings increase of about $500 million from $999.7 million today.

    Uncover how DexCom's forecasts yield a $94.12 fair value, a 6% upside to its current price.

    Exploring Other Perspectives

    DXCM 1-Year Stock Price Chart
    DXCM 1-Year Stock Price Chart

    You can see how views diverge here: the most pessimistic analysts were only assuming about US$6.5 billion of revenue and US$1.2 billion of earnings by 2029, so this new reimbursement driven momentum and trial evidence could challenge their slower adoption thesis and may eventually shift those forecasts.

    Explore 4 other fair value estimates on DexCom - why the stock might be worth just $94.12!

    Reach Your Own Conclusion

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    • A great starting point for your DexCom research is our analysis highlighting 3 key rewards that could impact your investment decision.
    • Our free DexCom research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate DexCom's overall financial health at a glance.

    Ready For A Different Approach?

    Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.